Efficacy of recombinant interferon α-2b in the complex therapy of COVID-19

Q4 Medicine

Infektsionnye Bolezni Pub Date : 2021-01-01 DOI:10.20953/1729-9225-2021-3-24-29

V. Krasnov, A. A. Katirkina, P. G. Zubarov, A. Levina, G. S. Bragina, E. N. Vyzhlova

{"title":"Efficacy of recombinant interferon α-2b in the complex therapy of COVID-19","authors":"V. Krasnov, A. A. Katirkina, P. G. Zubarov, A. Levina, G. S. Bragina, E. N. Vyzhlova","doi":"10.20953/1729-9225-2021-3-24-29","DOIUrl":null,"url":null,"abstract":"Objective. To evaluate the efficacy and safety of VIFERON® (recombinant interferon α-2b) rectal suppositories and gel for external and local use in the complex therapy of COVID-19 in adult patients. Patients and methods. 140 patients with COVID-19 were included in a prospective comparative controlled research study. The main group consisted of 71 patients who received standard therapy for coronavirus infection in combination with VIFERON® (rectal suppositories 3.000.000 IU for 1 supp. 3 times a day and gel 36.000 IU/g 5 times a day on the surface of nasal mucosa and palatine tonsils for 14 days); the comparison group – 69 patients who received standard therapy. Results. Patients who received VIFERON® complex therapy demonstrated more rapid clinical improvement by reducing the duration of symptoms of weakness and intoxication compared to the patients who received only standard therapy. The high activity of VIFERON® in elimination rate of SARS-CoV-2 RNA in nasopharyngeal samples was shown. The use of VIFERON® made it possible to achieve a stable concentration of IL-6 in the blood serum during the entire follow-up period. There were no adverse events associated with the administration of VIFERON®. Conclusion. The results obtained indicate the superiority of therapy with the inclusion of VIFERON® over standard therapy. Given the favorable safety profile, the studied regimen can be recommended for the treatment of adult patients, especially from risk groups, where the possibilities of conventional etiotropic therapy are limited due to possible toxicological effects. Key words: VIFERON®, human recombinant interferon α-2b, COVID-19 coronavirus infection","PeriodicalId":37794,"journal":{"name":"Infektsionnye Bolezni","volume":"1 1","pages":""},"PeriodicalIF":0.0000,"publicationDate":"2021-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Infektsionnye Bolezni","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.20953/1729-9225-2021-3-24-29","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q4","JCRName":"Medicine","Score":null,"Total":0}

引用次数: 0

Abstract

Objective. To evaluate the efficacy and safety of VIFERON® (recombinant interferon α-2b) rectal suppositories and gel for external and local use in the complex therapy of COVID-19 in adult patients. Patients and methods. 140 patients with COVID-19 were included in a prospective comparative controlled research study. The main group consisted of 71 patients who received standard therapy for coronavirus infection in combination with VIFERON® (rectal suppositories 3.000.000 IU for 1 supp. 3 times a day and gel 36.000 IU/g 5 times a day on the surface of nasal mucosa and palatine tonsils for 14 days); the comparison group – 69 patients who received standard therapy. Results. Patients who received VIFERON® complex therapy demonstrated more rapid clinical improvement by reducing the duration of symptoms of weakness and intoxication compared to the patients who received only standard therapy. The high activity of VIFERON® in elimination rate of SARS-CoV-2 RNA in nasopharyngeal samples was shown. The use of VIFERON® made it possible to achieve a stable concentration of IL-6 in the blood serum during the entire follow-up period. There were no adverse events associated with the administration of VIFERON®. Conclusion. The results obtained indicate the superiority of therapy with the inclusion of VIFERON® over standard therapy. Given the favorable safety profile, the studied regimen can be recommended for the treatment of adult patients, especially from risk groups, where the possibilities of conventional etiotropic therapy are limited due to possible toxicological effects. Key words: VIFERON®, human recombinant interferon α-2b, COVID-19 coronavirus infection

查看原文本刊更多论文

重组干扰素α-2b复合治疗COVID-19的疗效观察

目标。目的评价VIFERON®(重组干扰素α-2b)直肠栓剂和凝胶外用和局部应用在成人COVID-19综合治疗中的疗效和安全性。患者和方法。140例COVID-19患者纳入了一项前瞻性比较对照研究。主要组71例患者接受冠状病毒感染标准治疗联合VIFERON®(直肠栓剂300000.000 IU, 1次，每日3次，凝胶36000 IU/g，每日5次，鼻黏膜和腭扁桃体表面，连续14天);对照组为69例接受标准治疗的患者。结果。与仅接受标准治疗的患者相比，接受VIFERON®复合治疗的患者通过缩短虚弱和中毒症状的持续时间，表现出更快的临床改善。VIFERON®在鼻咽样品中对SARS-CoV-2 RNA的清除率具有较高的活性。使用VIFERON®可以在整个随访期间实现血清中IL-6的稳定浓度。没有与VIFERON®给药相关的不良事件。结论。所获得的结果表明含有VIFERON®的治疗优于标准治疗。鉴于良好的安全性，研究方案可推荐用于成人患者的治疗，特别是来自危险群体的患者，在这些人群中，由于可能的毒理学效应，传统致病因治疗的可能性有限。关键词:VIFERON®，人重组干扰素α-2b, COVID-19冠状病毒感染

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Infektsionnye Bolezni Medicine-Infectious Diseases

CiteScore

1.30

自引率

0.00%

发文量

期刊介绍： The journal publishes original research works, reviews of literature, lectures, methodological recommendations, clinical observations. Main topics: problems of etiology, pathogenesis, clinical manifestations of infectious diseases, new techniques and methods of their diagnosis, prevention and treatment; special attention is paid to the problems of antibacterial and antiviral therapy, the use of immunoglobulins and interferons, and also to intensive therapy of critical states. The journal is in the List of leading scientific journals and periodicals of the Supreme Attestation Committee, where the principal results of doctoral dissertations should be published.